Ja-Hong Kim, MD
Urology · Los Angeles, CANPI 1942321393
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,278 of the $11,115 with a category attached, or 65.5%. 12 manufacturers reported payments, led by Boston Scientific at 44.7% of the total. Reporting peaked in 2023 at $4,245 and has fallen 85.8% since, to $605 in 2025.
Across 161 payments — averaging $69.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$4K
- Urogen Pharma, Inc.$552
- Rochester Medical Corporation$402
- AbbVie$381
- C. R. Bard, Inc. & Subsidiaries$282
- plus $657 from 6 others
What the payments were for
- Grants$3,83735%
- Food & beverage$7,27865%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $4,965 |
| Medtronic(2 entities) | 58 | $3,877 |
| Urogen Pharma, Inc. | 4 | $552 |
| Rochester Medical Corporation | 33 | $402 |
| AbbVie | 13 | $381 |
| C. R. Bard, Inc. & Subsidiaries | 21 | $282 |
| Procept Biorobotics Corporation | 2 | $230 |
| Coloplast | 2 | $149 |
| Axonics, Inc. | 2 | $106 |
| BD | 2 | $76 |
| Merck | 4 | $64 |
| Calyxo, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,465
- GENERAL ERECTILE DYSFUNCTION$1,581
- JELMYTO$552
- AMS 700 CXR RTE KIT$348
- AquaBeam Robotic System$205
- AMS 700$142
- Advantage System$108
- TACTRA$102
How this compares
$11,115 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 220 | $161,421 |
| MyrbetriqMirabegron | 143 | $110,087 |
| Fosfomycin Tromethamine | 76 | $20,462 |
| Methenamine Hippurate | 235 | $19,132 |
| Estradiol | 175 | $14,338 |
| PremarinEstrogens, Conjugated | 17 | $7,363 |
| Trospium Chloride | 74 | $4,753 |
| YuvafemEstradiol | 14 | $2,512 |
| Desmopressin Acetate | 25 | $2,064 |
| Trimethoprim | 35 | $1,800 |
| Metronidazole | 27 | $1,306 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 57 | $1,202 |
| Tamsulosin Hcl | 85 | $847 |
| Solifenacin Succinate | 20 | $818 |
| Imipramine Hcl | 25 | $741 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.